| Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism.N Engl J Med | PMID 40162636无 PMCID | 2025-Apr-10 | 0.90 | This is a Phase III randomized trial in humans with active cancer. It has a time-to-event primary endpoint (recurrent VTE). However, the intervention (apixaban) is an anticoagulant used for VTE prevention, not a cancer treatment drug. The study is not a drug intervention trial for oncology treatment efficacy (e.g., OS, PFS, DFS) but for a supportive/complication-prevention endpoint. Therefore, it does not meet the 'drug intervention' criterion for an oncology efficacy trial as defined. | 待处理 |
| Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis.Nat Commun | PMID 40204778PMC11982359 | 2025-Apr-09 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Laboratory markers predicting tofacitinib efficacy in Japanese patients with rheumatoid arthritis: A pooled analysis of Phase 2/3 randomised controlled clinical trials.Mod Rheumatol | PMID 39657989无 PMCID | 2025-Apr-08 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Disease activity and glucocorticoid tapering patterns in Japanese patients with systemic lupus erythematosus treated with anifrolumab: Post hoc analysis of the Japanese subpopulation of the TULIP-2 study.Mod Rheumatol | PMID 39801286无 PMCID | 2025-Apr-08 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV.AIDS Res Ther | PMID 40197415PMC11978100 | 2025-Apr-07 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Assessment of heterogeneity according to hospital or medical experience factors in outcomes of chemotherapy for advanced biliary tract cancer: a post-hoc analysis of JCOG1113.Jpn J Clin Oncol | PMID 39775866PMC11973634 | 2025-Apr-06 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 已完成 |
| First-line pembrolizumab-axitinib versus sunitinib in metastatic RCC: subgroup analysis of patients enrolled in the phase 3 KEYNOTE-426 in Eastern Asia.Jpn J Clin Oncol | PMID 39815637PMC12042800 | 2025-Apr-06 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 已完成 |
| Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis.J Crohns Colitis | PMID 40168091PMC11976722 | 2025-Apr-04 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons.N Engl J Med | PMID 39602624无 PMCID | 2025-Apr-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Alteplase for Posterior Circulation Ischemic Stroke at 4.5 to 24 Hours.N Engl J Med | PMID 40174223无 PMCID | 2025-Apr-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Impact of RSV Prevention in Infancy on Prevalence of Asthma Among 9-14-Year-old Native American Children in the Southwest United States.Pediatr Infect Dis J | PMID 40208934无 PMCID | 2025-Apr-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis.Hepatology | PMID 39250515无 PMCID | 2025-Apr-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexate.Rheumatology (Oxford) | PMID 39331638PMC11963078 | 2025-Apr-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Weight and Metabolic Changes With Long-Acting Cabotegravir and Rilpivirine or Bictegravir/Emtricitabine/Tenofovir Alafenamide.J Acquir Immune Defic Syndr | PMID 39676239PMC11841724 | 2025-Apr-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial.Int J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:FIGURE 1:森林图/亚组分析图;FIGURE 2:森林图/亚组分析图;FIGURE 3:非 KM 图。 | PMID 39739622PMC11789451 | 2025-Apr-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Bioequivalence of Preservative-Free and Preserved Omidenepag Isopropyl 0.002% Ophthalmic Solutions in Patients With Primary Open Angle Glaucoma or Ocular Hypertension: Phase 3 DAISY Study.J Glaucoma | PMID 39750078PMC11952686 | 2025-Apr-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Baricitinib Dose Reduction in Patients With Rheumatoid Arthritis Achieving Sustained Disease Control: Final Results From the RA-BEYOND Study.J Rheumatol | PMID 39814441无 PMCID | 2025-Apr-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Prognostic Value of FDG PET Metabolic Parameters Before and After 42 Gy of Radiochemotherapy in Patients with Inoperable Stage III Nonsmall Cell Lung Cancer.J Nucl Med | PMID 40015915无 PMCID | 2025-Apr-01 | 0.85 | The study is a randomized Phase II/III oncology trial with time-to-event endpoints, but the intervention described is a radiotherapy dose modification strategy (boost vs. standard) without a specific drug-containing arm. The abstract mentions radiochemotherapy in the methods but does not specify any drug intervention in the analyzed groups or results, making drug intervention unclear and not explicitly established. Therefore, it is excluded. | 待处理 |
| Port Delivery System With Ranibizumab vs Monitoring in Nonproliferative Diabetic Retinopathy Without Macular Edema: The Pavilion Randomized Clinical Trial.JAMA Ophthalmol | PMID 40048178PMC11886866 | 2025-Apr-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema: The Pagoda Randomized Clinical Trial.JAMA Ophthalmol | PMID 40048197PMC11886869 | 2025-Apr-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tumor burden and heterogenous treatment effect of apalutamide in metastatic castration-sensitive prostate cancer.Cancer | PMID 40106307PMC11922167 | 2025-Apr-01 | 0.70 | The record describes a subgroup/heterogeneity analysis of a Phase III randomized trial (TITAN) comparing apalutamide vs. placebo. While it meets several criteria (oncology, human, randomized, Phase III, time-to-event endpoints), it is not the primary or definitive result report of the trial. The report type is 'subgroup', which is excluded per the rules. | 已完成 |
| Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m2 in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist.Diabetes Obes Metab | PMID 39821928PMC11885088 | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The Benefit of Combining Docetaxel with Androgen Deprivation Therapy in Localized and Metastatic Hormone-sensitive Prostate Cancer is Predicted by ERG Expression: An Analysis of Two GETUG Phase 3 Trials.Eur Urol Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39034169无 PMCID | 2025-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Health-related quality of life in cutaneous T-cell lymphoma: A post hoc analysis of a phase 3 trial in mycosis fungoides and Sézary syndrome.J Eur Acad Dermatol Venereol | PMID 39315857PMC11934017 | 2025-Apr | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel Trial.Eur Urol Oncol | PMID 39384451无 PMCID | 2025-Apr | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Efficacy and Safety of Ranibizumab Biosimilar QL1205 in Neovascular Age-Related Macular Degeneration: A Phase III Randomized Trial.Ophthalmol Retina | PMID 39389463无 PMCID | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Retinal Fluid and Thickness Fluctuations in Archway Trial for Port Delivery System with Ranibizumab versus Monthly Ranibizumab Injections.Ophthalmol Retina | PMID 39447871无 PMCID | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine versus a quadrivalent meningococcal conjugate vaccine in adults in India: an observer-blind, randomised, active-controlled, phase 2/3 study.Lancet Infect Dis | PMID 39521012无 PMCID | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Vadadustat Three Times Weekly in Patients With Anemia Due to Dialysis-Dependent CKD.Am J Kidney Dis | PMID 39521398无 PMCID | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Visual Loss in Geographic Atrophy: Learnings from the Lampalizumab Trials.Ophthalmology | PMID 39581330无 PMCID | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A randomized phase III study to compare efficacy and safety of BAT2206 (proposed ustekinumab biosimilar) with reference ustekinumab in patients with moderate to severe plaque psoriasis.J Am Acad Dermatol | PMID 39592058无 PMCID | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Dietary Habits of Individuals With Primary Sclerosing Cholangitis-Poor Fat-Soluble Vitamin Intake and Dietary Quality.Liver Int | PMID 39601354PMC11907217 | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial.Lancet Infect Dis | PMID 39608389无 PMCID | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC.J Thorac Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39622410无 PMCID | 2025-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial.J Clin Oncol | PMID 39637340PMC11949205 | 2025-Apr | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 部分完成 |
| Efficacy and safety of sotatercept across ranges of cardiac index in patients with pulmonary arterial hypertension: A pooled analysis of PULSAR and STELLAR.J Heart Lung Transplant | PMID 39645016无 PMCID | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48.Liver Int | PMID 39648559PMC11907224 | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma.Ann Oncol | PMID 39672382PMC12459081 | 2025-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| A phase III, randomized, controlled noninferiority trial to study the efficacy and safety of imipenem/cilastatin/relebactam (IMI/REL) vs piperacillin/tazobactam (PIP/TAZ) in patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP).Int J Infect Dis | PMID 39674398无 PMCID | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Association that Neuroimaging and Clinical Measures Have with Change in Arm Impairment in a Phase 3 Stroke Recovery Trial.Ann Neurol | PMID 39676623无 PMCID | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| LIBELULE: A Randomized Phase III Study to Evaluate the Clinical Relevance of Early Liquid Biopsy in Patients With Suspicious Metastatic Lung Cancer.J Thorac Oncol | PMID 39694415无 PMCID | 2025-Apr | 0.85 | The study is a Phase III randomized trial in human oncology, but it does not meet two key eligibility criteria: (1) The primary endpoint is time to treatment initiation (TTI), which is a diagnostic/process measure, not a clinical efficacy time-to-event endpoint (e.g., OS, PFS). (2) The intervention is a diagnostic liquid biopsy procedure versus standard diagnostic care; there is no experimental drug-containing intervention. | 待处理 |
| Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial.Ann Oncol | PMID 39706335PMC12184433 | 2025-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Glepaglutide, a Long-Acting Glucagon-like Peptide-2 Analogue, Reduces Parenteral Support in Patients With Short Bowel Syndrome: A Phase 3 Randomized Controlled Trial.Gastroenterology | PMID 39708985无 PMCID | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: Week 52 results from a phase 3b, randomized, double-blind, placebo-controlled trial.J Am Acad Dermatol | PMID 39722400无 PMCID | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Cardiovascular, kidney and safety outcomes with canagliflozin in older adults: A combined analysis from the CANVAS Program and CREDENCE trial.Diabetes Obes Metab | PMID 39781601无 PMCID | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials.Diabetes Obes Metab | PMID 39789843PMC11885085 | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Alkalinised lidocaine as an anaesthetic before onabotulinumtoxinA injections. a randomised trial.BJU Int | PMID 39797697PMC11913603 | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase 3, Randomized, Comparison Study of Intracameral Bimatoprost Implant 10 µg and Selective Laser Trabeculoplasty.Am J Ophthalmol | PMID 39800203无 PMCID | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial.Diabetologia | PMID 39820580PMC11950020 | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Individualized transfusion decisions to minimize adverse cardiovascular outcomes in patients with acute myocardial infarction and anemia.Am Heart J | PMID 39826701PMC12696691 | 2025-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |